CN108602861A - 用于治疗疼痛的组合物和方法 - Google Patents
用于治疗疼痛的组合物和方法 Download PDFInfo
- Publication number
- CN108602861A CN108602861A CN201680062855.4A CN201680062855A CN108602861A CN 108602861 A CN108602861 A CN 108602861A CN 201680062855 A CN201680062855 A CN 201680062855A CN 108602861 A CN108602861 A CN 108602861A
- Authority
- CN
- China
- Prior art keywords
- fusion protein
- toxin
- domain
- btx
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 269
- 208000002193 Pain Diseases 0.000 title claims abstract description 85
- 230000036407 pain Effects 0.000 title claims abstract description 71
- 238000000034 method Methods 0.000 title claims abstract description 41
- 102000037865 fusion proteins Human genes 0.000 claims abstract description 545
- 108020001507 fusion proteins Proteins 0.000 claims abstract description 545
- 239000003053 toxin Substances 0.000 claims abstract description 437
- 231100000765 toxin Toxicity 0.000 claims abstract description 436
- 108030001720 Bontoxilysin Proteins 0.000 claims abstract description 310
- 210000000929 nociceptor Anatomy 0.000 claims abstract description 228
- 241000193738 Bacillus anthracis Species 0.000 claims abstract description 188
- 230000008685 targeting Effects 0.000 claims abstract description 49
- 241000193155 Clostridium botulinum Species 0.000 claims abstract description 7
- 108700012359 toxins Proteins 0.000 claims description 436
- 230000027455 binding Effects 0.000 claims description 242
- 102000005962 receptors Human genes 0.000 claims description 232
- 108020003175 receptors Proteins 0.000 claims description 232
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 149
- 108091005804 Peptidases Proteins 0.000 claims description 107
- 239000004365 Protease Substances 0.000 claims description 96
- 210000004899 c-terminal region Anatomy 0.000 claims description 96
- 102000035195 Peptidases Human genes 0.000 claims description 94
- 108090000623 proteins and genes Proteins 0.000 claims description 83
- 102000004169 proteins and genes Human genes 0.000 claims description 75
- 101000796085 Homo sapiens Anthrax toxin receptor 2 Proteins 0.000 claims description 74
- 235000018102 proteins Nutrition 0.000 claims description 72
- 241000193403 Clostridium Species 0.000 claims description 65
- 230000005945 translocation Effects 0.000 claims description 65
- 102000014914 Carrier Proteins Human genes 0.000 claims description 63
- 108091008324 binding proteins Proteins 0.000 claims description 63
- 102100031325 Anthrax toxin receptor 2 Human genes 0.000 claims description 57
- 230000001665 lethal effect Effects 0.000 claims description 51
- 231100000518 lethal Toxicity 0.000 claims description 50
- 102000000583 SNARE Proteins Human genes 0.000 claims description 46
- 108010041948 SNARE Proteins Proteins 0.000 claims description 46
- 210000004027 cell Anatomy 0.000 claims description 45
- 239000002581 neurotoxin Substances 0.000 claims description 45
- 231100000618 neurotoxin Toxicity 0.000 claims description 45
- 101710138657 Neurotoxin Proteins 0.000 claims description 41
- 206010030113 Oedema Diseases 0.000 claims description 40
- 102000004961 Furin Human genes 0.000 claims description 39
- 108090001126 Furin Proteins 0.000 claims description 39
- 102000016607 Diphtheria Toxin Human genes 0.000 claims description 37
- 108010053187 Diphtheria Toxin Proteins 0.000 claims description 37
- 108090000862 Ion Channels Proteins 0.000 claims description 35
- 102000004310 Ion Channels Human genes 0.000 claims description 35
- 210000002569 neuron Anatomy 0.000 claims description 31
- 235000018417 cysteine Nutrition 0.000 claims description 29
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 28
- 108050003126 conotoxin Proteins 0.000 claims description 27
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims description 26
- 108010052164 Sodium Channels Proteins 0.000 claims description 25
- 102000018674 Sodium Channels Human genes 0.000 claims description 25
- 102000004190 Enzymes Human genes 0.000 claims description 24
- 108090000790 Enzymes Proteins 0.000 claims description 24
- 231100000065 noncytotoxic Toxicity 0.000 claims description 23
- 230000002020 noncytotoxic effect Effects 0.000 claims description 23
- 102000003922 Calcium Channels Human genes 0.000 claims description 22
- 108090000312 Calcium Channels Proteins 0.000 claims description 22
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 claims description 18
- 101000640020 Homo sapiens Sodium channel protein type 11 subunit alpha Proteins 0.000 claims description 17
- 101900161471 Pseudomonas aeruginosa Exotoxin A Proteins 0.000 claims description 17
- 230000006378 damage Effects 0.000 claims description 17
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 claims description 16
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 claims description 16
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 claims description 16
- 210000000172 cytosol Anatomy 0.000 claims description 16
- 102100033974 Sodium channel protein type 11 subunit alpha Human genes 0.000 claims description 14
- 108010039491 Ricin Proteins 0.000 claims description 12
- 102000039446 nucleic acids Human genes 0.000 claims description 12
- 108020004707 nucleic acids Proteins 0.000 claims description 12
- 150000007523 nucleic acids Chemical class 0.000 claims description 12
- 108010079723 Shiga Toxin Proteins 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 9
- 108091007433 antigens Proteins 0.000 claims description 9
- 102000036639 antigens Human genes 0.000 claims description 9
- XOAUGYVLRSCGBG-UHFFFAOYSA-N protx ii Chemical compound O=C1NC(CCC(N)=O)C(=O)NC(CCCCN)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(CCSC)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC(C(C)O)C(=O)NC(C(NC(CC(O)=O)C(=O)NC(CO)C(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CSSCC(NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(N)=N)NC2=O)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(CC=3C4=CC=CC=C4NC=3)C(O)=O)C(=O)N3)=O)CSSCC2NC(=O)C(C(C)C)NC(=O)C(CCSC)NC(=O)CNC(=O)C(CCC(O)=O)NC(=O)C3CSSCC1NC(=O)C(N)CC1=CC=C(O)C=C1 XOAUGYVLRSCGBG-UHFFFAOYSA-N 0.000 claims description 9
- 230000012202 endocytosis Effects 0.000 claims description 8
- 108091006146 Channels Proteins 0.000 claims description 7
- 108010049048 Cholera Toxin Proteins 0.000 claims description 7
- 102000009016 Cholera Toxin Human genes 0.000 claims description 7
- 210000005036 nerve Anatomy 0.000 claims description 7
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 6
- 230000001681 protective effect Effects 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 239000002708 spider venom Substances 0.000 claims description 6
- 210000002845 virion Anatomy 0.000 claims description 6
- 206010043376 Tetanus Diseases 0.000 claims description 5
- 230000003993 interaction Effects 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- 239000013612 plasmid Substances 0.000 claims description 4
- 231100000331 toxic Toxicity 0.000 claims description 2
- 230000002588 toxic effect Effects 0.000 claims description 2
- 239000013603 viral vector Substances 0.000 claims description 2
- 208000027418 Wounds and injury Diseases 0.000 claims 16
- 208000014674 injury Diseases 0.000 claims 16
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 13
- 238000005336 cracking Methods 0.000 claims 4
- 101500000960 Bacillus anthracis Protective antigen PA-63 Proteins 0.000 claims 2
- 229930188089 Holothurin Natural products 0.000 claims 2
- MAWWITJOQDJRJF-ADBICINLSA-M holothurin Chemical compound [Na+].O[C@@H]1[C@@H](OC)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H](OC[C@H]([C@@H]3O)OS([O-])(=O)=O)O[C@@H]3C([C@H]4[C@](C=5[C@H]([C@@]6(CC[C@]7(O)[C@](C)([C@H]8OC(C)(C)CC8)OC(=O)[C@@]76[C@@H](O)C=5)C)CC4)(C)CC3)(C)C)O[C@@H]2C)O)O[C@H](C)[C@H]1O MAWWITJOQDJRJF-ADBICINLSA-M 0.000 claims 2
- 229960005548 palytoxin Drugs 0.000 claims 2
- 230000017105 transposition Effects 0.000 claims 2
- 239000004927 clay Substances 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
- 229940053031 botulinum toxin Drugs 0.000 abstract description 280
- 101710194807 Protective antigen Proteins 0.000 description 484
- 108010055044 Tetanus Toxin Proteins 0.000 description 91
- 229940118376 tetanus toxin Drugs 0.000 description 91
- 108091008700 nociceptors Proteins 0.000 description 73
- 239000012634 fragment Substances 0.000 description 66
- 235000019419 proteases Nutrition 0.000 description 52
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 43
- 229940024606 amino acid Drugs 0.000 description 38
- 235000001014 amino acid Nutrition 0.000 description 38
- 241000251511 Holothuroidea Species 0.000 description 33
- 238000003776 cleavage reaction Methods 0.000 description 33
- 230000007017 scission Effects 0.000 description 33
- 150000001413 amino acids Chemical class 0.000 description 32
- 125000000539 amino acid group Chemical group 0.000 description 30
- 239000000306 component Substances 0.000 description 29
- 230000006870 function Effects 0.000 description 29
- 230000003197 catalytic effect Effects 0.000 description 23
- 239000003937 drug carrier Substances 0.000 description 23
- 229940088598 enzyme Drugs 0.000 description 23
- 239000000546 pharmaceutical excipient Substances 0.000 description 23
- 102000004196 processed proteins & peptides Human genes 0.000 description 22
- 108010076504 Protein Sorting Signals Proteins 0.000 description 21
- 239000012528 membrane Substances 0.000 description 20
- 125000003275 alpha amino acid group Chemical group 0.000 description 19
- 230000002255 enzymatic effect Effects 0.000 description 19
- 239000003112 inhibitor Substances 0.000 description 19
- 238000011282 treatment Methods 0.000 description 19
- 210000001163 endosome Anatomy 0.000 description 18
- 229920001184 polypeptide Polymers 0.000 description 16
- 239000011148 porous material Substances 0.000 description 16
- 108030001722 Tentoxilysin Proteins 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 108010013369 Enteropeptidase Proteins 0.000 description 11
- 102100029727 Enteropeptidase Human genes 0.000 description 11
- 108010067372 Pancreatic elastase Proteins 0.000 description 11
- 102000016387 Pancreatic elastase Human genes 0.000 description 11
- 108010030544 Peptidyl-Lys metalloendopeptidase Proteins 0.000 description 11
- 101710118538 Protease Proteins 0.000 description 11
- 108090001109 Thermolysin Proteins 0.000 description 11
- 108090000631 Trypsin Proteins 0.000 description 11
- 102000004142 Trypsin Human genes 0.000 description 11
- 230000004927 fusion Effects 0.000 description 11
- 230000000670 limiting effect Effects 0.000 description 11
- 125000001288 lysyl group Chemical group 0.000 description 11
- 235000019833 protease Nutrition 0.000 description 11
- 239000012588 trypsin Substances 0.000 description 11
- 108091008604 NGF receptors Proteins 0.000 description 10
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 description 10
- 230000000903 blocking effect Effects 0.000 description 10
- 108090001092 clostripain Proteins 0.000 description 10
- 230000003834 intracellular effect Effects 0.000 description 10
- 230000004048 modification Effects 0.000 description 10
- 238000012986 modification Methods 0.000 description 10
- 102100031323 Anthrax toxin receptor 1 Human genes 0.000 description 8
- 230000001419 dependent effect Effects 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000001537 neural effect Effects 0.000 description 8
- 238000001243 protein synthesis Methods 0.000 description 8
- -1 serotypes) Proteins 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 102000043136 MAP kinase family Human genes 0.000 description 7
- 108091054455 MAP kinase family Proteins 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000004296 neuralgia Diseases 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 206010005063 Bladder pain Diseases 0.000 description 6
- 206010058019 Cancer Pain Diseases 0.000 description 6
- 208000000094 Chronic Pain Diseases 0.000 description 6
- 208000001640 Fibromyalgia Diseases 0.000 description 6
- 208000000112 Myalgia Diseases 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 208000013465 muscle pain Diseases 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 208000021722 neuropathic pain Diseases 0.000 description 6
- 230000003957 neurotransmitter release Effects 0.000 description 6
- 208000009935 visceral pain Diseases 0.000 description 6
- 150000008574 D-amino acids Chemical group 0.000 description 5
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 5
- 101150108558 PAD1 gene Proteins 0.000 description 5
- 101150094373 Padi4 gene Proteins 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 102000030621 adenylate cyclase Human genes 0.000 description 5
- 108060000200 adenylate cyclase Proteins 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 210000003594 spinal ganglia Anatomy 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 230000009278 visceral effect Effects 0.000 description 5
- 102100023995 Beta-nerve growth factor Human genes 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 description 4
- 108010025020 Nerve Growth Factor Proteins 0.000 description 4
- 241000239226 Scorpiones Species 0.000 description 4
- 108010039069 anthrax toxin receptors Proteins 0.000 description 4
- 230000005754 cellular signaling Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000012636 effector Substances 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000003780 insertion Methods 0.000 description 4
- 230000037431 insertion Effects 0.000 description 4
- 229940053128 nerve growth factor Drugs 0.000 description 4
- 210000000653 nervous system Anatomy 0.000 description 4
- 230000001473 noxious effect Effects 0.000 description 4
- 230000009437 off-target effect Effects 0.000 description 4
- 238000006384 oligomerization reaction Methods 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 210000001044 sensory neuron Anatomy 0.000 description 4
- 230000032258 transport Effects 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 102000005701 Calcium-Binding Proteins Human genes 0.000 description 3
- 108010045403 Calcium-Binding Proteins Proteins 0.000 description 3
- 102000000584 Calmodulin Human genes 0.000 description 3
- 108010041952 Calmodulin Proteins 0.000 description 3
- 241001638933 Cochlicella barbara Species 0.000 description 3
- 101000796095 Homo sapiens Anthrax toxin receptor 1 Proteins 0.000 description 3
- 208000007101 Muscle Cramp Diseases 0.000 description 3
- 241000282376 Panthera tigris Species 0.000 description 3
- 101710084578 Short neurotoxin 1 Proteins 0.000 description 3
- 208000005392 Spasm Diseases 0.000 description 3
- 241000239292 Theraphosidae Species 0.000 description 3
- 101710182532 Toxin a Proteins 0.000 description 3
- 102000036861 Zinc-dependent endopeptidases Human genes 0.000 description 3
- 108091006982 Zinc-dependent endopeptidases Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 150000001408 amides Chemical group 0.000 description 3
- 229940065181 bacillus anthracis Drugs 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000002041 carbon nanotube Substances 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000003040 nociceptive effect Effects 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 230000005062 synaptic transmission Effects 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- 108010085238 Actins Proteins 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 241000239290 Araneae Species 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 2
- 101710117524 Botulinum neurotoxin type B Proteins 0.000 description 2
- 101710117518 Botulinum neurotoxin type D Proteins 0.000 description 2
- 101710117520 Botulinum neurotoxin type F Proteins 0.000 description 2
- 101710117519 Botulinum neurotoxin type G Proteins 0.000 description 2
- 206010008631 Cholera Diseases 0.000 description 2
- 101000985023 Clostridium botulinum C phage Botulinum neurotoxin type C Proteins 0.000 description 2
- 102000010970 Connexin Human genes 0.000 description 2
- 108050001175 Connexin Proteins 0.000 description 2
- 241000017055 Dipluridae Species 0.000 description 2
- 101710088791 Elongation factor 2 Proteins 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 2
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 108010069023 botulinum toxin type E Proteins 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 230000003472 neutralizing effect Effects 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108010091748 peptide A Proteins 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108091008706 proprioceptors Proteins 0.000 description 2
- 235000004252 protein component Nutrition 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 238000002864 sequence alignment Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 239000002435 venom Substances 0.000 description 2
- 231100000611 venom Toxicity 0.000 description 2
- 210000001048 venom Anatomy 0.000 description 2
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 2
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102000009062 ADP Ribose Transferases Human genes 0.000 description 1
- 108010049290 ADP Ribose Transferases Proteins 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- 241001083548 Anemone Species 0.000 description 1
- 101710125943 Anthrax toxin receptor 1 Proteins 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 241000239223 Arachnida Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 101000585552 Bacillus anthracis Protective antigen Proteins 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241000237970 Conus <genus> Species 0.000 description 1
- 108010025905 Cystine-Knot Miniproteins Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 101710179441 Huwentoxin-IV Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical group O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010023203 Joint destruction Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 241000237852 Mollusca Species 0.000 description 1
- 101710167839 Morphogenetic protein Proteins 0.000 description 1
- 208000002231 Muscle Neoplasms Diseases 0.000 description 1
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 1
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 208000033952 Paralysis flaccid Diseases 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 101710081553 Psalmotoxin-1 Proteins 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 101710094933 Purotoxin-1 Proteins 0.000 description 1
- 102000005917 R-SNARE Proteins Human genes 0.000 description 1
- 108010005730 R-SNARE Proteins Proteins 0.000 description 1
- FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 1
- 206010041415 Spastic paralysis Diseases 0.000 description 1
- 102000004874 Synaptophysin Human genes 0.000 description 1
- 108090001076 Synaptophysin Proteins 0.000 description 1
- 102000013265 Syntaxin 1 Human genes 0.000 description 1
- 108010090618 Syntaxin 1 Proteins 0.000 description 1
- 241000618809 Vitales Species 0.000 description 1
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 description 1
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 description 1
- 241000399000 Weissella oryzae Species 0.000 description 1
- 102000036859 Zinc-dependent proteases Human genes 0.000 description 1
- 108091006973 Zinc-dependent proteases Proteins 0.000 description 1
- OKSSKVHGKYJNLL-LJRZAWCWSA-N [(3as,4r,9s,10as)-2,6-diamino-10,10-dihydroxy-9-sulfooxy-3a,4,8,9-tetrahydro-1h-pyrrolo[1,2-c]purin-4-yl]methoxycarbonylsulfamic acid Chemical compound OS(=O)(=O)NC(=O)OC[C@@H]1N=C(N)N2C[C@H](OS(O)(=O)=O)C(O)(O)[C@@]22N=C(N)N[C@H]21 OKSSKVHGKYJNLL-LJRZAWCWSA-N 0.000 description 1
- 241001147796 [Clostridium] spiroforme Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000012867 alanine scanning Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 238000001815 biotherapy Methods 0.000 description 1
- 230000000981 bystander Effects 0.000 description 1
- 230000011496 cAMP-mediated signaling Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 108020001778 catalytic domains Proteins 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000002925 chemical effect Effects 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 210000002932 cholinergic neuron Anatomy 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 150000002019 disulfides Chemical class 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000002095 exotoxin Substances 0.000 description 1
- 231100000776 exotoxin Toxicity 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 208000028331 flaccid paralysis Diseases 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 239000003219 hemolytic agent Substances 0.000 description 1
- 229930186900 holotoxin Natural products 0.000 description 1
- MJMLBAPXMAOKDU-UHFFFAOYSA-N huwentoxin iv Chemical compound C1SSCC(C(NC(CSSCC(NC(=O)C(N)CCC(O)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(C(C)CC)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCCN)C(=O)NC(C)C(=O)N2)C(=O)NC(CCCCN)C(=O)NC(CO)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(CC(C)C)C(=O)NC(C(=O)N3)C(C)C)=O)NC(=O)C(CCC(N)=O)NC(=O)C(CC(O)=O)NC(=O)C(CC(N)=O)NC(=O)C(CO)NC(=O)C4CCCN4C(=O)C(CC(N)=O)NC(=O)C2CSSCC3C(=O)NC(CO)C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=2C3=CC=CC=C3NC=2)C(=O)NC1C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CCC(N)=O)C(=O)NC(C(C)CC)C(N)=O)CC1=CC=C(O)C=C1 MJMLBAPXMAOKDU-UHFFFAOYSA-N 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 108091006086 inhibitor proteins Proteins 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 231100000745 invertebrate toxin Toxicity 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000001503 joint Anatomy 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000002077 muscle cancer Diseases 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 231100000189 neurotoxic Toxicity 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000007481 next generation sequencing Methods 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 230000037324 pain perception Effects 0.000 description 1
- 230000008050 pain signaling Effects 0.000 description 1
- LICLJUGDURFZIM-UHFFFAOYSA-N pctx1 Chemical compound N1C(=O)C(CO)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCCNC(N)=N)NC(=O)C(CCCCN)NC(=O)C(CC=2C3=CC=CC=C3NC=2)NC(=O)C(NC(=O)C(CCC(O)=O)NC(=O)C(CC(C)C)NC(=O)CNC(=O)C(CCC(O)=O)NC2=O)CSSCC(C(=O)NC(C(C)C)C(=O)NC(CC(N)=O)C(=O)NC(CCCNC(N)=N)C(=O)NC(CC=3N=CNC=3)C(=O)NCC(=O)NC(CC(O)=O)C(=O)N3)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CC=4C5=CC=CC=C5NC=4)NC(=O)C(CCCCN)NC(=O)C4CCCN4C(=O)C(C(C)CC)NC(=O)C(NC(=O)C(CC(O)=O)NC(=O)C(N)CCC(O)=O)CSSCC2NC(=O)C3CSSCC(C(=O)NC(C(C)C)C(=O)N2C(CCC2)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)N2C(CCC2)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(O)=O)NC(=O)C(C(C)C)NC(=O)C(CCC(O)=O)NC(=O)C1CC1=CC=CC=C1 LICLJUGDURFZIM-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 229930000184 phytotoxin Natural products 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- KECTXGMVIXOQAO-UHFFFAOYSA-N purotoxin 1 Chemical compound N1C(=O)C(CCCNC(N)=N)NC(=O)C(C(C)CC)NC(=O)CNC(=O)C(CCCCN)NC(=O)C(CCC(O)=O)NC(=O)C(C)NC(=O)C(NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)CN)CSSCC(C(NC(C(=O)NCC(=O)NC(CC(C)C)C(=O)NC(CCCCN)C(=O)N2)C(C)O)=O)NC(=O)C(NC3=O)CSSCC(C(=O)NC(CCCNC(N)=N)C(=O)NC(CCCCN)C(=O)NC(CCCCN)C(N)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)C(CC(N)=O)NC(=O)C(CC=4C=CC(O)=CC=4)NC(=O)CNC(=O)C(CO)NC(=O)C(C)NC(=O)C(CC(N)=O)NC4=O)CSSCC4NC(=O)C(CCCCN)NC(=O)C2CSSCC1C(=O)NC(CC(O)=O)C(=O)NC(CC(O)=O)C(=O)NC(C(C)CC)C(=O)NC3CC1=CNC=N1 KECTXGMVIXOQAO-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 230000003335 steric effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 201000009032 substance abuse Diseases 0.000 description 1
- 231100000736 substance abuse Toxicity 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000003977 synaptic function Effects 0.000 description 1
- 238000009121 systemic therapy Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 210000000427 trigeminal ganglion Anatomy 0.000 description 1
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 1
- 229960002811 ziconotide Drugs 0.000 description 1
- KNJNGVKTAFTUFL-OCMUWRIYSA-N ω-conotoxin Chemical compound N([C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1C(N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CSSC1)C(N)=O)=O)=O)C(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1 KNJNGVKTAFTUFL-OCMUWRIYSA-N 0.000 description 1
- 108091058550 ω-conotoxin Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/32—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bacillus (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/07—Bacillus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/25—Shigella (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/28—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Vibrionaceae (F)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Botany (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210610P | 2015-08-27 | 2015-08-27 | |
| US62/210,610 | 2015-08-27 | ||
| PCT/US2016/049106 WO2017035508A1 (en) | 2015-08-27 | 2016-08-26 | Compositions and methods for treatment of pain |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108602861A true CN108602861A (zh) | 2018-09-28 |
Family
ID=58101095
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680062855.4A Pending CN108602861A (zh) | 2015-08-27 | 2016-08-26 | 用于治疗疼痛的组合物和方法 |
| CN201680062362.0A Pending CN108350039A (zh) | 2015-08-27 | 2016-08-26 | 用于治疗疼痛的组合物和方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201680062362.0A Pending CN108350039A (zh) | 2015-08-27 | 2016-08-26 | 用于治疗疼痛的组合物和方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US11753633B2 (enExample) |
| EP (2) | EP3341391A4 (enExample) |
| JP (2) | JP2018530315A (enExample) |
| KR (2) | KR20180070563A (enExample) |
| CN (2) | CN108602861A (enExample) |
| AU (2) | AU2016310521A1 (enExample) |
| BR (2) | BR112018003782A2 (enExample) |
| CA (2) | CA2994560A1 (enExample) |
| EA (1) | EA201890587A1 (enExample) |
| MX (1) | MX2018002183A (enExample) |
| WO (2) | WO2017035507A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220354962A1 (en) * | 2015-05-12 | 2022-11-10 | The Trustees Of The University Of Pennsylvania | Rapid production of bispecific antibodies from off-the-shelf iggs with high yield and purity |
| TW201718627A (zh) * | 2015-06-11 | 2017-06-01 | 梅茲製藥有限兩合公司 | 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞 |
| US11753633B2 (en) | 2015-08-27 | 2023-09-12 | President And Fellows Of Harvard College | Compositions and methods for treatment of pain |
| GB201607901D0 (en) | 2016-05-05 | 2016-06-22 | Ipsen Biopharm Ltd | Chimeric neurotoxins |
| PL3481852T3 (pl) * | 2016-07-08 | 2023-07-24 | Children's Medical Center Corporation | Nowa neurotoksyna botulinowa i jej pochodne |
| EP3687566A2 (en) * | 2017-09-29 | 2020-08-05 | Children's Medical Center Corporation | A neurotoxin-like toxin and uses thereof |
| CA3220194A1 (en) | 2018-01-29 | 2019-08-01 | Ipsen Biopharm Limited | Non-neuronal snare-cleaving botulinum neurotoxins |
| EP3752128B1 (de) * | 2018-02-16 | 2025-01-15 | preclinics discovery GmbH | Nukleinsäure-basiertes botulinum neurotoxin zur therapeutischen anwendung |
| EP3802834A4 (en) * | 2018-05-30 | 2022-08-03 | The Governing Council of the University of Toronto | METHODS AND KITS FOR IDENTIFYING A PROTEIN RELATED TO RECEPTOR-LIGAND INTERACTIONS |
| JP7193628B2 (ja) * | 2018-07-06 | 2022-12-20 | 北京天成新脉生物技▲術▼有限公司 | 低ａｄｃｃ／ｃｄｃ機能性モノクローナル抗体、及びその調製方法と使用 |
| EP4134133A1 (en) * | 2018-07-31 | 2023-02-15 | Snoretox Pty Ltd | Pegylated tetanus neurotoxins and treatment of hypotonia |
| WO2020116686A1 (ko) | 2018-12-06 | 2020-06-11 | 고려대학교 산학협력단 | 인간 항-antxr 키메라 항원 수용체 및 이의 용도 |
| US20230120677A1 (en) * | 2020-01-21 | 2023-04-20 | Trustees Of Dartmouth College | Immunologically optimized botulinum toxin light chain variants |
| JP2023522534A (ja) * | 2020-02-03 | 2023-05-31 | プレマス バイオテック プライベート リミテッド | 発現が困難なタンパク質を発現させるための、組換え発現プラットフォーム、構築物、および方法 |
| WO2021173916A1 (en) * | 2020-02-27 | 2021-09-02 | President And Fellows Of Harvard College | Nociceptor neurons control cancer immunosurveillance |
| KR102728382B1 (ko) * | 2022-10-12 | 2024-11-14 | 주식회사 알케미어 | 보툴리눔 독소의 경쇄 변이체 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1371424A (zh) * | 1999-08-25 | 2002-09-25 | 阿勒根销售公司 | 可活化的重组神经毒素 |
| US20130336974A1 (en) * | 2011-01-10 | 2013-12-19 | President And Fellows Of Harvard College | Method for delivering agents into cells using bacterial toxins |
| CN103649317A (zh) * | 2011-05-16 | 2014-03-19 | 辛它可辛有限公司 | 治疗性融合蛋白 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4737462A (en) | 1982-10-19 | 1988-04-12 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β |
| US4518584A (en) | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| IL99552A0 (en) | 1990-09-28 | 1992-08-18 | Ixsys Inc | Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
| AU720857B2 (en) | 1995-12-13 | 2000-06-15 | President And Fellows Of Harvard College | Use of toxin peptides and/or affinity handles for delivery compounds into cells |
| US5723125A (en) | 1995-12-28 | 1998-03-03 | Tanox Biosystems, Inc. | Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide |
| GB9526733D0 (en) | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
| US6365185B1 (en) | 1998-03-26 | 2002-04-02 | University Of Cincinnati | Self-destructing, controlled release peroral drug delivery system |
| AUPP627498A0 (en) | 1998-10-02 | 1998-10-22 | University Of Queensland, The | Novel peptides - i |
| US6767896B1 (en) | 1999-01-29 | 2004-07-27 | Cognetix, Inc. | Conotoxin peptides |
| DK1214340T3 (da) | 1999-09-24 | 2005-04-04 | Us Gov Health & Human Serv | Muterede antigen-proteiner, der beskytter mod anthrax-toxiner, og som specifikt målretter celler, der indeholder store mængder af celleoverflade-metalproteinaser eller plasminogenaktivator-receptorer |
| CA2396529A1 (en) | 1999-12-30 | 2001-07-12 | University Of Utah Research Foundation | O-superfamily conotoxin peptides |
| JP2006507800A (ja) * | 2002-06-07 | 2006-03-09 | ラージ・スケール・バイオロジー・コーポレイション | 可撓性ワクチンアセンブリおよびワクチン送達プラットフォーム |
| DE102004043009A1 (de) | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| EP1858546A4 (en) | 2005-03-04 | 2009-03-04 | Biorexis Pharmaceutical Corp | MODIFIED TRANSFERRINFUSION PROTEINS |
| ATE463506T1 (de) | 2005-09-19 | 2010-04-15 | Allergan Inc | Mit clostriedientoxin aktivierbare clostridientoxine |
| KR20140130524A (ko) | 2005-11-08 | 2014-11-10 | 애더리스 래버러토리즈 | Ｍｕ-코노톡신 펩티드 및 국소 마취제로서 그의 용도 |
| CA2601537A1 (en) | 2006-03-14 | 2007-09-20 | Allergan, Inc. | Modified clostridial toxins with altered targeting capabilities for clostridial toxin target cells |
| GB0610867D0 (en) | 2006-06-01 | 2006-07-12 | Syntaxin Ltd | Treatment of pain |
| CA2658260A1 (en) | 2006-07-11 | 2008-01-17 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for clostridial toxin target cells |
| EP2038299A2 (en) | 2006-07-11 | 2009-03-25 | Allergan, Inc. | Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells |
| US9284358B2 (en) | 2006-07-18 | 2016-03-15 | University Of Utah Research Foundation | Conotoxin peptides |
| US20150044210A1 (en) | 2012-02-23 | 2015-02-12 | President And Fellows Of Harvard College | Modified microbial toxin receptor for delivering agents into cells |
| CA2874436A1 (en) | 2012-05-21 | 2013-11-28 | Massachusetts Institute Of Technology | Translocation of non-natural chemical entities through anthrax protective antigen pore |
| US20140056870A1 (en) * | 2012-08-27 | 2014-02-27 | Allergan, Inc. | Fusion proteins |
| WO2014088928A1 (en) | 2012-12-03 | 2014-06-12 | President And Fellows Of Harvard College | Methods for making targeted protein toxins by sortase-mediated protein ligation |
| GB201407525D0 (en) | 2014-04-29 | 2014-06-11 | Syntaxin Ltd | Manufacture of recombinant clostridium botulinum neurotoxins |
| US11753633B2 (en) | 2015-08-27 | 2023-09-12 | President And Fellows Of Harvard College | Compositions and methods for treatment of pain |
-
2016
- 2016-08-26 US US15/755,544 patent/US11753633B2/en active Active
- 2016-08-26 US US15/755,543 patent/US10704035B2/en active Active
- 2016-08-26 CA CA2994560A patent/CA2994560A1/en not_active Abandoned
- 2016-08-26 JP JP2018510813A patent/JP2018530315A/ja active Pending
- 2016-08-26 EP EP16840234.5A patent/EP3341391A4/en active Pending
- 2016-08-26 CN CN201680062855.4A patent/CN108602861A/zh active Pending
- 2016-08-26 WO PCT/US2016/049099 patent/WO2017035507A1/en not_active Ceased
- 2016-08-26 MX MX2018002183A patent/MX2018002183A/es unknown
- 2016-08-26 WO PCT/US2016/049106 patent/WO2017035508A1/en not_active Ceased
- 2016-08-26 BR BR112018003782A patent/BR112018003782A2/pt not_active Application Discontinuation
- 2016-08-26 EP EP16840235.2A patent/EP3341392A4/en active Pending
- 2016-08-26 EA EA201890587A patent/EA201890587A1/ru unknown
- 2016-08-26 KR KR1020187008538A patent/KR20180070563A/ko not_active Withdrawn
- 2016-08-26 KR KR1020187008537A patent/KR20180050679A/ko not_active Withdrawn
- 2016-08-26 AU AU2016310521A patent/AU2016310521A1/en not_active Abandoned
- 2016-08-26 CA CA2994729A patent/CA2994729A1/en not_active Abandoned
- 2016-08-26 AU AU2016312685A patent/AU2016312685A1/en not_active Abandoned
- 2016-08-26 BR BR112018003794A patent/BR112018003794A2/pt not_active Application Discontinuation
- 2016-08-26 JP JP2018511085A patent/JP2018525021A/ja active Pending
- 2016-08-26 CN CN201680062362.0A patent/CN108350039A/zh active Pending
-
2020
- 2020-05-27 US US16/884,893 patent/US11104892B2/en active Active
-
2021
- 2021-08-13 US US17/402,323 patent/US20220033795A1/en not_active Abandoned
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1371424A (zh) * | 1999-08-25 | 2002-09-25 | 阿勒根销售公司 | 可活化的重组神经毒素 |
| US20130336974A1 (en) * | 2011-01-10 | 2013-12-19 | President And Fellows Of Harvard College | Method for delivering agents into cells using bacterial toxins |
| CN103649317A (zh) * | 2011-05-16 | 2014-03-19 | 辛它可辛有限公司 | 治疗性融合蛋白 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018530315A (ja) | 2018-10-18 |
| JP2018525021A (ja) | 2018-09-06 |
| AU2016310521A1 (en) | 2018-03-01 |
| US11104892B2 (en) | 2021-08-31 |
| MX2018002183A (es) | 2018-05-28 |
| KR20180050679A (ko) | 2018-05-15 |
| EP3341392A1 (en) | 2018-07-04 |
| US11753633B2 (en) | 2023-09-12 |
| EA201890587A1 (ru) | 2018-09-28 |
| WO2017035507A1 (en) | 2017-03-02 |
| AU2016312685A1 (en) | 2018-03-01 |
| EP3341391A1 (en) | 2018-07-04 |
| US20180244731A1 (en) | 2018-08-30 |
| BR112018003782A2 (pt) | 2018-09-25 |
| EP3341392A4 (en) | 2019-01-23 |
| EP3341391A4 (en) | 2019-03-06 |
| CA2994729A1 (en) | 2017-03-02 |
| US20180251740A1 (en) | 2018-09-06 |
| US10704035B2 (en) | 2020-07-07 |
| CN108350039A (zh) | 2018-07-31 |
| US20200362325A1 (en) | 2020-11-19 |
| BR112018003794A2 (pt) | 2018-09-25 |
| US20220033795A1 (en) | 2022-02-03 |
| KR20180070563A (ko) | 2018-06-26 |
| WO2017035508A1 (en) | 2017-03-02 |
| CA2994560A1 (en) | 2017-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11104892B2 (en) | Compositions and methods for treatment of pain | |
| JP5764072B2 (ja) | 改変非細胞毒性プロテアーゼ | |
| US20220211823A1 (en) | Clostridial Neurotoxins Comprising an Exogenous Activation Loop | |
| CN112105379A (zh) | 神经毒素样毒素及其用途 | |
| JP2012518403A5 (enExample) | ||
| CN107438670A (zh) | 嵌合多肽 | |
| AU2025200548A1 (en) | Non-toxic clostridial neurotoxin polypeptides for use in treating neurological disorders | |
| JP2020039349A (ja) | かゆみの抑制 | |
| US20240158773A1 (en) | Engineered botulinum neurotoxin a protease domain with improved efficacy | |
| EP4594341A1 (en) | Clostridial neurotoxins comprising an activating exogenous protease cleavage site | |
| HK1261168A1 (en) | Compositions and methods for treatment of pain | |
| AU2022242859A1 (en) | Clostridial neurotoxins comprising an exogenous activation loop | |
| EP3911742A1 (en) | Sortase-labelled clostridium neurotoxins | |
| RU2801120C2 (ru) | Меченные сортазой нейротоксины клостридий | |
| WO2024069175A1 (en) | Clostridial neurotoxins comprising an activating endosomal protease cleavage site | |
| US20240082369A1 (en) | Improved receptor-binding domain of botulinum neurotoxin a and uses thereof | |
| EA047022B1 (ru) | Клостридиальные нейротоксины, содержащие экзогенную петлю активации |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1261168 Country of ref document: HK |
|
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180928 |